COVID-19: UK approves Actemra as a therapeutic drug: Imperial College London
[London]
British Prime Minister Boris Johnson:
At a press conference on January 7, it was announced that “Actemra (tocilizumab) will soon be approved as a COVID-19 treatment.”
Tocilizumab and salilumab, these two treatments, will soon be given to patients.
Actemra:
The world’s first interleukin 6 (IL-6) inhibitor.
It was jointly developed by Osaka University and Chugai Pharmaceutical.
In the announcement of Imperial College London, UK
Tocilizumab in 353 patients,
Forty-eight patients received salilumab
Separately, a control group of 402 people was set up.
The majority of patients were treated with corticosteroids and received oxygen inhalation.
Mortality rate:
In the control group, it was 35.8%, compared with
28% with tocilizumab
Administration of salilumab increased to 22.2%,
It turns out that the mortality rate was suppressed.
Result of this time:
COVID-19 To prevent aggravation
In addition to the steroidal anti-inflammatory drug dexamethasone,
It shows that the IL-6 inhibitor is effective.
It’s great in that it can mitigate the threat of COVID-19.
-Yahoo! News
https://news.yahoo.co.jp/byline/kimuramasato/20210108-00216702/
New corona: Japan’s rheumatism drug, effective for corona treatment
-Announced by the British government-
2021/01/09
【London】
British Government:
On the 7th, it was announced that the therapeutic agents for rheumatoid arthritis “tocilizumab” and “salilumab” are effective in treating the new coronavirus.
Tocilizumab:
Developed by Tadamitsu Kishimoto, former president of Osaka University and Chugai Pharmaceutical, it is known by the brand name of “Actemra”.
A clinical study supported by the British government has shown an effect.
Administration of dexamethasone:
The anti-inflammatory drug “dexamethasone” was administered to patients in the intensive care unit.
The mortality rate with conventional treatment was 35.8%.
Administer tocilizumab:
On the other hand, when additional tocilizumab was used within 24 hours of transport, the mortality rate dropped to 27.3%.
Additional administration of two drugs:
As a result, the risk of death is reduced by 24% when two additional drugs are administered.
The period for patients to enter the intensive care unit was also shortened by 7 to 10 days.
In the UK, it will be used for patients who are taken to the intensive care unit in the future.
International: News: Yomiuri Shimbun Online
https://www.yomiuri.co.jp/world/20210108-OYT1T50219/
Covid-19 Treatments: Arthritis Drugs Reduced Deaths, ICU Time in Study
Study showed reduction in mortality and ICU times with Actemra
Sanofi and Regeneron’s Kevzara also included in research
The U.K. will start using a Roche Holding AG arthritis drug
to treat critically ill Covid-19 patients after a study showed that it reduced mortality and shortened recovery times in intensive care.
Some 27% of critically ill patients
who got the Roche arthritis drug Actemra or a similar treatment from Sanofi and Regeneron Pharmaceuticals Inc. died in the hospital, compared with about 36% of those who didn’t get them,
an Imperial College London research team said.
Those treated with the medicines
were able to be released from the hospital an average of a week earlier, the study found.
Roche will also continue its own studies on Actemra in Covid-19, the Swiss drugmaker said in a statement.
In previous studies, Actemra had reduced the need for patients to be ventilated and appeared to help them leave hospitals earlier.
Bloomberg